Lamivudine, nevirapine, and zidovudine are used together for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This fixed-dose combination is part of antiretroviral therapy and helps reduce viral load, improve immune function, and slow disease progression. It is prescribed for eligible patients as part of a comprehensive HIV management plan.

This combination works by targeting HIV replication through multiple mechanisms. Lamivudine and zidovudine are nucleoside reverse transcriptase inhibitors (NRTIs) that block the reverse transcriptase enzyme, preventing the virus from copying its genetic material. Nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to the same enzyme and inhibits its function. Together, these drugs reduce viral replication, lower viral load, and help maintain immune system health.

This medication is taken orally in tablet form as prescribed by a healthcare provider. It should be taken with food, and the tablet must be swallowed whole without crushing, chewing, or breaking it. The dosage and duration depend on the patient’s age, body weight, and medical condition. It is important to follow the prescribed schedule strictly and not stop the medication without medical advice to maintain treatment effectiveness.

Common side effects include nausea, diarrhea, headache, dizziness, cough, and difficulty sleeping. While these are generally mild, some patients may experience more serious side effects such as liver problems, skin reactions, hematologic toxicity (reduced blood cell counts), lactic acidosis, or muscle weakness. Patients should seek immediate medical attention if they notice severe symptoms such as rash, breathing difficulty, or unusual fatigue.

This medication should not be used in patients with known hypersensitivity to any of its components. It is not recommended for individuals with anemia, neutropenia, or those weighing less than 35 kg. Caution is required in patients with liver disease (including hepatitis B or C), kidney problems, or active skin conditions. Regular monitoring of blood counts, liver function, and overall health is essential during treatment. The medication is not recommended during pregnancy or breastfeeding, and patients should inform their doctor about all medications they are taking to avoid drug interactions.

Lamivudine, nevirapine, and zidovudine provide a well-established combination therapy for managing HIV infection. By targeting the virus through multiple pathways, it helps maintain long-term viral suppression and supports immune health. However, strict adherence to treatment and regular monitoring are crucial for achieving the best outcomes. With proper medical guidance, this combination remains an effective option in HIV care.